This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The designation addresses the unmet need for prevention of H5N1, which remains a global health risk, and a phase 1 trial of the vaccine was initiated in November 2024.
A study found that children aged 6 months or younger who are not eligible for vaccination were at the highest risk for hospitalization due to SARS-CoV-2.
A co-administration option for both vaccinations can increase the likelihood of older adults completing the vaccination series and improve health outcomes for the patient population.
Study authors recommend that healthcare personnel consider prioritizing influenza vaccination for patients with recent cardiovascular diseases (CVDs) in light of new evidence.
Researchers explored an alternative pharmacist education intervention as a way of improving pharmacist-patient conversations and decreasing vaccine hesitancy among patients.
Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.
The findings support the need for improved vaccination coverage to prevent the resurgence of previously eliminated infectious diseases in the United States.
Researchers compared the safety and reactogenicity of simultaneous doses of recombinant zoster vaccine paired with 2 separate types of inactivated influenza vaccines.
Posters presented at the APhA 2024 Annual Meeting and Exposition discussed pharmacist barriers in pediatric immunizations, a novel meningococcal vaccine, and the need for inpatient reviews of vaccination history.
A recent poll showed that some parents do not discuss vaccines with their child’s regular doctor, with many choosing to not have their child receive any vaccines.
Seasonal influenza kills hundreds of thousands of people every year due to a constantly changing virus and highly inefficient vaccine production. A universal flu vaccine could deal with the first problem, and mRNA technology with the second.
Jean-Venable Goode, BSPharm, PharmD, and Jeff Goad, PharmD, MPH, presented on the most notable vaccine updates from the past year and how they impact pharmacy practice.
The estimated efficacy of the vaccine against documented infection for children and adolescents during the Omicron wave was 74.3% and 85.5%, respectively.
Researchers explored ideas of simplifying the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.
Keep your pharmacy vaccine-ready for your youngest patients with the most current influenza vaccination information from the American Academy of Pediatrics.
Goode, PharmD, director of the PGY1 Community Based Residency Program at Virginia Commonwealth University, discussed the new vaccine guidelines from ACIP. Jean-Venable R.
The vaccine showed an overall efficacy of 80% in the per-protocol analysis, with a risk reduction of 6.1 typhoid infections per 1000 vaccinated children.
Prophylactic HPV vaccines have demonstrated remarkable efficacy, exceeding 98%, and they are already proving to be effective in the prevention of anogenital warts, precancerous lesions, and cancer alike.
Lauren Angelo, PharmD, MBA, discussed current vaccination sentiments across the country and how misinformation has contributed to declining rates among US patients.
The shots should still be free to individuals because of rules barring out-of-pocket costs for such vaccinations. Pfizer Inc. and Moderna Inc. have indicated that they are going to price their shots at between $110 and $130.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Vaccines Related Topics 
691 
Let's personalize your content